Ocean Biomedical, Inc. – NASDAQ:OCEA
Ocean Biomedical stock price today
$0.004
-0.56
-99.35%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 25 minutes
Ocean Biomedical stock price monthly change
-48.47%
month
Ocean Biomedical stock price quarterly change
-48.47%
quarter
Ocean Biomedical stock price yearly change
-4.83%
year
Ocean Biomedical key metrics
Market Cap | 20.22M |
Enterprise value | 12.83M |
P/E | -93.4 |
EV/Sales | N/A |
EV/EBITDA | -6.79 |
Price/Sales | N/A |
Price/Book | -2.64 |
PEG ratio | -1.94 |
EPS | -6.14 |
Revenue | N/A |
EBITDA | -23.85M |
Income | -154.74M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOcean Biomedical stock price history
Ocean Biomedical stock forecast
Ocean Biomedical financial statements
| Dec 2022 | 0 | 410.05K | |
|---|---|---|---|
| Mar 2023 | 0 | -128.03M | |
| Jun 2023 | 0 | -13.02M | |
| Sep 2023 | 0 | -14.08M |
| 2027 | 0 | -17.45M |
|---|
Analysts Price target
Financials & Ratios estimates
| 2024-04-15 | -0.15 | -0.53 |
|---|
| Dec 2022 | 110911324 | 6.61M | 5.96% |
|---|---|---|---|
| Mar 2023 | 24978000 | 23.43M | 93.82% |
| Jun 2023 | 20921000 | 29.32M | 140.16% |
| Sep 2023 | 1030999 | 76.25M | 7396.22% |
| Dec 2022 | -143.8K | -1.05M | 1.05M |
|---|---|---|---|
| Mar 2023 | -2.65M | 0 | 2.92M |
| Jun 2023 | -4.78M | 0 | 6.63M |
| Sep 2023 | -1.13M | 0 | 0 |
Ocean Biomedical alternative data
| Aug 2023 | 9 |
|---|---|
| Sep 2023 | 9 |
| Oct 2023 | 9 |
| Nov 2023 | 9 |
| Dec 2023 | 9 |
| Jan 2024 | 9 |
| Feb 2024 | 9 |
| Mar 2024 | 9 |
| Apr 2024 | 9 |
| May 2024 | 9 |
| Jun 2024 | 9 |
| Jul 2024 | 9 |
Ocean Biomedical other data
3.69%
+3.69%
of OCEA is owned by hedge funds
97.43K
+97.43K
shares is hold by hedge funds
-
What's the price of Ocean Biomedical stock today?
One share of Ocean Biomedical stock can currently be purchased for approximately $0.
-
When is Ocean Biomedical's next earnings date?
Unfortunately, Ocean Biomedical's (OCEA) next earnings date is currently unknown.
-
Does Ocean Biomedical pay dividends?
No, Ocean Biomedical does not pay dividends.
-
How much money does Ocean Biomedical make?
Ocean Biomedical has a market capitalization of 20.22M. Ocean Biomedical earned 565.47K US dollars in net income (profit) last year or -$0.53 on an earnings per share basis.
-
What is Ocean Biomedical's stock symbol?
Ocean Biomedical, Inc. is traded on the NASDAQ under the ticker symbol "OCEA".
-
What is Ocean Biomedical's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Ocean Biomedical?
Shares of Ocean Biomedical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Ocean Biomedical have?
As Jul 2024, Ocean Biomedical employs 9 workers.
-
When Ocean Biomedical went public?
Ocean Biomedical, Inc. is publicly traded company for more then 3 years since IPO on 8 Nov 2021.
-
What is Ocean Biomedical's official website?
The official website for Ocean Biomedical is oceanbiomedical.com.
-
Where are Ocean Biomedical's headquarters?
Ocean Biomedical is headquartered at Room 325, 55 Claverick Street, Providence, RI.
-
How can i contact Ocean Biomedical?
Ocean Biomedical's mailing address is Room 325, 55 Claverick Street, Providence, RI and company can be reached via phone at +40 14447375.
Ocean Biomedical company profile:
Ocean Biomedical, Inc.
oceanbiomedical.comExchange:
NASDAQ
Full time employees:
9
Industry:
Biotechnology
Sector:
Healthcare
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company is developing mono-specific and bi-specific humanized monoclonal antibodies (mAb) product candidates targeting Chi3l1 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. It is also developing three product candidates based on the WPDS platform, including a malaria vaccine candidate; a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP); and a small molecule malaria therapeutic candidate targeting PfGARP, as well as a product candidate for the treatment of COVID-19 in hospitalized patients. The company was incorporated in 2019 and is based in Providence, Rhode Island.
Room 325, 55 Claverick Street
Providence, RI 02903
Providence, RI 02903
CIK: 0001836612
ISIN: US67644C1045
CUSIP: 67644P105
